Special Issue

Recent Advancement in the Diagnosis and Management of Gastrointestinal Disorders

Message from the Guest Editor

Current clinical practice is moving towards precision medicine. Advances in understanding the pathophysiology of various gastrointestinal disorders have made it possible to identify the meaning of clinical features and develop accurate diagnostic methods or targeted therapies. The representative features of precision medicine are artificial intelligence technologies, including deep learning or machine learning. Artificial intelligence is rapidly being applied to medical practice in the context of the automatic identification, classification, and prediction of important features of gastrointestinal disorders, and it is expected to affect our clinical practice. Combining big data analysis with artificial intelligence has the potential to increase accuracy because analyzing large amounts of data can uncover unexpected associations or new trends. The purpose of this Special Issue is to highlight recent advances in the context of diagnosis or treatment for various gastrointestinal disorders.

Guest Editor

Dr. Chang Seok Bang

Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24253, Gangwon-do, Republic of Korea

Deadline for manuscript submissions

closed (20 October 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

**Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed**

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).